Skip to content

Testing people with conditions suggesting HIV could pick up more recent infections, Europe-wide study finds

Raltegravir continues to perform well at four years

Dolutegravir is potent but twice-daily works better for integrase-resistant

How common is neurocognitive impairment in people with HIV? It depends who you compare them with

Help when you're troubled: getting the right psychological support

Saving face: GMFA's sexual health messaging service

Taking charge of our future

Growing pain

Barriers to care: immigration removal centres and HIV